JP2018525447A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018525447A5 JP2018525447A5 JP2018530646A JP2018530646A JP2018525447A5 JP 2018525447 A5 JP2018525447 A5 JP 2018525447A5 JP 2018530646 A JP2018530646 A JP 2018530646A JP 2018530646 A JP2018530646 A JP 2018530646A JP 2018525447 A5 JP2018525447 A5 JP 2018525447A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- halogenated
- optionally
- formula
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 39
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 102100021257 Beta-secretase 1 Human genes 0.000 claims 7
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000002971 oxazolyl group Chemical group 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- -1 heteroaryl halide Chemical class 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 230000001603 reducing effect Effects 0.000 claims 2
- 230000006999 cognitive decline Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 0 CN(C1=O)C(N)=NC1(c1ccc(*)c(*)c1)C1=C**C(*)=C1 Chemical compound CN(C1=O)C(N)=NC1(c1ccc(*)c(*)c1)C1=C**C(*)=C1 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562210945P | 2015-08-27 | 2015-08-27 | |
| US62/210,945 | 2015-08-27 | ||
| PCT/US2016/049271 WO2017035529A1 (en) | 2015-08-27 | 2016-08-29 | Compositions for app-selective bace inhibition and uses therfor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020152650A Division JP2021001188A (ja) | 2015-08-27 | 2020-09-11 | Ａｐｐ選択的ｂａｃｅ阻害のための組成物およびそのための使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018525447A JP2018525447A (ja) | 2018-09-06 |
| JP2018525447A5 true JP2018525447A5 (https=) | 2019-08-29 |
Family
ID=58101012
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018530646A Pending JP2018525447A (ja) | 2015-08-27 | 2016-08-29 | Ａｐｐ選択的ｂａｃｅ阻害のための組成物およびそのための使用 |
| JP2020152650A Pending JP2021001188A (ja) | 2015-08-27 | 2020-09-11 | Ａｐｐ選択的ｂａｃｅ阻害のための組成物およびそのための使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020152650A Pending JP2021001188A (ja) | 2015-08-27 | 2020-09-11 | Ａｐｐ選択的ｂａｃｅ阻害のための組成物およびそのための使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11142505B2 (https=) |
| EP (1) | EP3341362B1 (https=) |
| JP (2) | JP2018525447A (https=) |
| KR (1) | KR20180090778A (https=) |
| CN (1) | CN108349905A (https=) |
| AU (1) | AU2016311502B2 (https=) |
| CA (2) | CA2996542C (https=) |
| WO (1) | WO2017035529A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2899938C (en) | 2013-02-12 | 2021-10-19 | Buck Institute For Research On Aging | Hydantoins that modulate bace-mediated app processing |
| EP3341362B1 (en) * | 2015-08-27 | 2023-07-05 | Nantneuro, LLC | Compositions for app-selective bace inhibition and uses therfor |
| US20210101879A1 (en) * | 2018-03-01 | 2021-04-08 | The Regents Of The University Of California | AMYLOID PROTEIN-SELECTIVE BACE INHIBITORS (ASBIs) FOR ALZHEIMER?S DISEASE |
| US11926599B1 (en) | 2023-10-23 | 2024-03-12 | King Faisal University | 1-(2-chlorobenzylideneamino)-5,5-diphenylimidazolidine-2,4-dione as an antimicrobial compound |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2217250T3 (es) | 1990-06-15 | 2004-11-01 | Scios Inc. | Mamifero transgenico, no humano que muestra la patologia de formacion amiloides de la enfermedad de alzheimer. |
| ES2236682T5 (es) | 1991-01-21 | 2011-03-31 | Elan Pharmaceuticals, Inc. | Ensayo y modelo para la enfermedad de alzheimer. |
| AU671093B2 (en) | 1992-01-07 | 1996-08-15 | Elan Pharmaceuticals, Inc. | Transgenic animal models for alzheimer's disease |
| US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
| AU702293B2 (en) | 1993-10-27 | 1999-02-18 | Athena Neurosciences, Inc. | Transgenic animals harboring APP allele having Swedish mutation |
| US5877399A (en) | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
| US5744346A (en) | 1995-06-07 | 1998-04-28 | Athena Neurosciences, Inc. | β-secretase |
| JPH11507538A (ja) | 1995-06-07 | 1999-07-06 | アテナ ニューロサイエンシズ インコーポレイティド | β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ |
| WO2000003819A1 (en) | 1998-07-17 | 2000-01-27 | The Penn State Research Foundation | Full form roll finishing technique |
| PL205294B1 (pl) | 1998-09-24 | 2010-03-31 | Upjohn Co | Izolowany lub oczyszczony polipeptyd, oczyszczony lub izolowany polinukleotyd, wektor, wektor ekspresyjny, komórka gospodarza, sposób wytwarzania polipeptydu, sposoby identyfikowania czynnika obniżającego, modulującego lub hamującego aktywność, zastosowanie takiego czynnika, izolowany kwas nukleinowy, obejmujący go wektor i ich zastosowanie, sposoby zmniejszania komórkowego wytwarzania beta amyloidu i zastosowanie antysensownego reagenta |
| BRPI0512213A (pt) * | 2004-06-16 | 2008-02-19 | Wyeth Corp | método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto |
| AU2006266167A1 (en) * | 2005-06-30 | 2007-01-11 | Wyeth | Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for beta-secretase modulation |
| TW200738683A (en) * | 2005-06-30 | 2007-10-16 | Wyeth Corp | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation |
| JP2009509957A (ja) * | 2005-09-26 | 2009-03-12 | ワイス | β−セクレターゼ阻害剤としてのアミノ−５−［４−（ジフルオロメトキシ）フェニル］−５−フェニルイミダゾロン化合物 |
| AU2006333049A1 (en) | 2005-12-19 | 2007-07-12 | Wyeth | 2-amino-5-piperidinylimidazolone compounds and use thereof for beta-secretase modulation |
| CL2008000791A1 (es) * | 2007-03-23 | 2008-05-30 | Wyeth Corp | Compuestos derivados de 2-amino-5-(4-difluorometoxi-fenil)-5-fenil-imidazolidin-4-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la actividad bace excesiva, tales como enferm |
| CA2899938C (en) * | 2013-02-12 | 2021-10-19 | Buck Institute For Research On Aging | Hydantoins that modulate bace-mediated app processing |
| US9980769B2 (en) | 2014-04-08 | 2018-05-29 | Ethicon Llc | Methods and devices for controlling motorized surgical devices |
| EP3341362B1 (en) | 2015-08-27 | 2023-07-05 | Nantneuro, LLC | Compositions for app-selective bace inhibition and uses therfor |
| US20200165225A1 (en) | 2017-06-28 | 2020-05-28 | Nantbio, Inc. | Bace1 inhibitors for treatment of alzheimer's disease |
| US20210101879A1 (en) | 2018-03-01 | 2021-04-08 | The Regents Of The University Of California | AMYLOID PROTEIN-SELECTIVE BACE INHIBITORS (ASBIs) FOR ALZHEIMER?S DISEASE |
-
2016
- 2016-08-29 EP EP16840254.3A patent/EP3341362B1/en active Active
- 2016-08-29 US US15/755,496 patent/US11142505B2/en active Active
- 2016-08-29 KR KR1020187008350A patent/KR20180090778A/ko not_active Ceased
- 2016-08-29 WO PCT/US2016/049271 patent/WO2017035529A1/en not_active Ceased
- 2016-08-29 CN CN201680053449.1A patent/CN108349905A/zh active Pending
- 2016-08-29 CA CA2996542A patent/CA2996542C/en active Active
- 2016-08-29 CA CA3096896A patent/CA3096896A1/en not_active Abandoned
- 2016-08-29 AU AU2016311502A patent/AU2016311502B2/en not_active Ceased
- 2016-08-29 JP JP2018530646A patent/JP2018525447A/ja active Pending
-
2020
- 2020-09-11 JP JP2020152650A patent/JP2021001188A/ja active Pending